| __timestamp | Pharming Group N.V. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4167274 | 5903000 |
| Thursday, January 1, 2015 | 5247851 | 2762000 |
| Friday, January 1, 2016 | 4925118 | 1114000 |
| Sunday, January 1, 2017 | 14930297 | 25573000 |
| Monday, January 1, 2018 | 25371768 | 6000000 |
| Tuesday, January 1, 2019 | 23921274 | 38845000 |
| Wednesday, January 1, 2020 | 25338236 | 50523000 |
| Friday, January 1, 2021 | 20182966 | 75463000 |
| Saturday, January 1, 2022 | 17562000 | 105767000 |
| Sunday, January 1, 2023 | 25212000 | 167512000 |
Cracking the code
In the dynamic world of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Pharming Group N.V. and Xenon Pharmaceuticals Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Pharming Group N.V. maintained a relatively stable cost structure, with a peak in 2018 at approximately 25 million, reflecting a strategic focus on cost management. In contrast, Xenon Pharmaceuticals Inc. experienced a dramatic increase, culminating in 2023 with a cost of revenue nearly 17 times higher than its 2014 figure. This surge highlights Xenon's aggressive expansion and investment in research and development. As the biotech industry continues to evolve, these companies exemplify different approaches to balancing growth and efficiency, offering valuable insights for investors and industry analysts alike.
Analyzing Cost of Revenue: Novartis AG and Xenon Pharmaceuticals Inc.
Amgen Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Cost of Revenue: Key Insights for BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Incyte Corporation and Pharming Group N.V.'s Expenses
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.'s Expenses
Cost of Revenue Comparison: Pharming Group N.V. vs PTC Therapeutics, Inc.
Cost of Revenue Trends: Pharming Group N.V. vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Pharming Group N.V. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Pharming Group N.V. and Galapagos NV's Expenses
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Xenon Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Xenon Pharmaceuticals Inc. and Wave Life Sciences Ltd.